On Jan. 12, 2021, the Tufts Center for the Study of Drug Development reported that ever more complex clinical trial designs were collecting much higher volumes of data from a variety of sources, intensifying pressure on drug sponsors to meet speed and efficiency goals.

Phase III clinical trials currently generatd an average of 3.6 million data points, three times the data collected by late stage trials 10 years ago, according to a newly completed study from Tufts CSDD.